Related Experiment Video
Updated: May 7, 2026

Xenopus laevis as a Model to Identify Translation Impairment
Published on: September 27, 2015
Isoguanosine-Induced ER Stress via AMPK Enhances Chemosensitivity in OSCC
1State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Research Unit of Oral Carcinogenesis and Management & Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Abstract:
Oral squamous cell carcinoma (OSCC) is the most common malignancy of the head and neck; however, the efficacy of existing treatment is limited and new effective strategies need to be explored. Our previous work demonstrates that isoguanosine (isoG) is a promising nucleoside molecule with superior self-assembly capability and significant anti-OSCC potential. However, the antitumor mechanism of isoG remains unclear. In this study, we reveal that the antiproliferative effect of isoG is mediated by its cellular metabolite, isoguanosine 5'-monophosphate (isoGMP), which induces excessive endoplasmic reticulum (ER) stress and cell death through adenosine monophosphate-activated protein kinase (AMPK) activation. IsoG activates AMPK and induces ER stress at low concentrations, with minimal impact on cell viability at these concentrations. To further explore the therapeutic potential of isoG, we investigated its role in modulating chemosensitivity. Our findings show that AMPK activation enhances the sensitivity of OSCC cells to 5-fluorouracil (5-FU), and the combination of isoG and 5-FU exhibits a synergistic anticancer effect. Building on the self-assembly characteristics of isoG, we developed an innovative treatment platform by introducing dynamic borate ester bonds to form an isoguanosine-phenylenediboronic acid-isoguanosine (isoGPBisoG) structure. When combined with 5-FU, this platform achieved remarkable therapeutic efficacy in 2 OSCC cell-derived xenograft models, with tumor inhibition rates of 71.0% and 56.6%, respectively, compared with control. These findings establish isoG as a potent enhancer of chemotherapeutic efficacy in OSCC via AMPK activation. More importantly, the isoGPBisoG and 5-FU combination represents a significant paradigm of a synergistic therapy platform. This novel approach offers a promising direction for the development of more effective OSCC treatments.
Insights
Isoguanosine (isoG) enhances oral cancer treatment by activating AMPK, inducing ER stress, and improving chemotherapy sensitivity. A novel isoG-based platform combined with 5-FU shows significant tumor inhibition in preclinical models.
Area of Science:
- Biochemistry
- Oncology
- Materials Science
Background:
- Oral squamous cell carcinoma (OSCC) presents limited treatment options.
- Isoguanosine (isoG) shows anti-OSCC potential but its mechanism is unknown.
- Developing novel therapeutic strategies for OSCC is crucial.
Purpose of the Study:
- To elucidate the antitumor mechanism of isoguanosine (isoG) in OSCC.
- To investigate isoG's role in modulating chemosensitivity.
- To develop and evaluate a novel isoG-based therapeutic platform for OSCC.
Main Methods:
- Investigated isoG's metabolite, isoguanosine 5'-monophosphate (isoGMP), and its effect on endoplasmic reticulum (ER) stress and adenosine monophosphate-activated protein kinase (AMPK) activation.
- Assessed the combined effect of isoG and 5-fluorouracil (5-FU) on OSCC cells.
- Developed an isoG-phenylenediboronic acid-isoG (isoGPBisoG) structure and evaluated its efficacy in combination with 5-FU in OSCC xenograft models.
Main Results:
- IsoG's antiproliferative effect is mediated by isoGMP, inducing ER stress and cell death via AMPK activation.
- AMPK activation by isoG enhances OSCC cell sensitivity to 5-FU, leading to synergistic anticancer effects.
- The isoGPBisoG and 5-FU combination demonstrated significant tumor inhibition (71.0% and 56.6%) in OSCC xenograft models.
Conclusions:
- Isoguanosine (isoG) is a potent enhancer of chemotherapeutic efficacy in OSCC through AMPK activation.
- The isoGPBisoG and 5-FU combination represents a promising synergistic therapy platform for OSCC.
- This novel approach offers a new direction for developing more effective OSCC treatments.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Stringent Response in E. coli

